HAYWARD, Calif., Sept. 30 Metabolex, Inc., abiopharmaceutical company focused on the discovery and development ofproprietary new therapeutics for the treatment of diabetes and relatedmetabolic disorders, announced that Robert L. Zerbe, M.D., has been elected toits Board of Directors.
Dr. Zerbe is the chief executive officer, director and co-founder ofQuatRx Pharmaceuticals, Inc., located in Ann Arbor, MI. Dr. Zerbe hasextensive experience in global clinical development and regulatory affairs.From 1982 to 2000, he held a variety of research and development positions,including managing director, Lilly Research Center U.K., senior vice presidentof worldwide clinical research and development at Parke Davis and senior vicepresident for Pfizer global research and development. He led the clinicaldevelopment programs for key products including Lipitor(R) and Neurontin(R).
"Dr. Zerbe will bring to the board a unique blend of clinical andregulatory experience in metabolic disease coupled with operational experiencein guiding development strategy in a small company," said Harold Van Wart,president and chief executive officer of Metabolex. "His expertise will bevaluable in advancing the four drugs currently in our pipeline as well asother promising preclinical candidates."
Dr. Zerbe earned his medical degree at Indiana University in 1975, andcompleted his post-doctoral work in internal medicine, endocrinology, andneuroendocrinology at Indiana and the National Institutes of Health. He alsoserves on the boards of AP Pharma, Aastrom Biosciences, AnesivaPharmaceuticals, and the Biotechnology Industry Organization Emerging SectionGoverning Body.
Metabolex is a privately-held biopharmaceutical company focused on thediscovery and development of proprietary new medicines for the treatment ofmetabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawnon its deep understanding of diabetes to create a large database of genesinvolved in diabetes and to build a rich pipeline of product candidates anddrug discovery targets. The company has four clinical-stage compounds:MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044,which has completed a Phase 2a trial; MBX-8025, currently being studied in aPhase 2 trial in patients with dyslipidemia; and MBX-2982, currently beingstudied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right todevelop and commercialize MBX-102/JNJ 39659100. For additional informationabout Metabolex and its development pipeline, visit http://www.metabolex.com.
SOURCE Metabolex, Inc.